BioSpace News Archive

LAVA Therapeutics N.V., an immuno-oncology company focused on developing its proprietary Gammabody™ platformof bispecific gamma delta T cell engagers to transform the treatment of cancer, announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2021.

Eli Lilly and Company announced that the U.S. Food and Drug Administration has issued a complete response letter for the Biologics License Application for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer.

The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age.

Protalix BioTherapeutics, Inc. today announced that it will release its financial results for fiscal year 2021 and provide a business update on Thursday, March 31, 2022.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and provided a corporate update for the fourth quarter and full year 2021, as well as outlook for 2022.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022.

ProMIS Neurosciences, Inc. announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.

BiondVax Pharmaceuticals Ltd. today announced the signing of definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (MPI), and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development of innovative nanosized antibodies (NanoAbs).

Calliditas Therapeutics AB announced that CEO Renée Aguiar-Lucander has subscribed for 175,000 shares through Calliditas’ warrant program 2018/2022.

Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29.